The US government has published the finalised 'maximum fair prices' (MFPs) for the first 10 medicines subject to Medicare negotiations under the Inflation Reduction Act (IRA), shortly after
Johnson & Johnson has three of its top-selling drugs in Medicare pricing negotiations – Stelara, Xarelto, and Imbruvica – but has said it does not expect a major hit to its finances nex
A Connecticut federal judge has sided with the US Department of Health and Human Services (HHS) in Boehringer Ingelheim's challenge to Medicare’s drug price negotiation programme, rejecting
In a US Presidential debate that was low on policy substance and high on hyperbole, falsehoods, and personal attacks, pharma industry issues played a minor role, but did crop up in ways bot
In another setback for the pharma industry, a US federal judge has rejected a bid to overturn the Medicare pricing negotiation brought by Bristol-Myers Squibb and Johnson